Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 37,134

Document Document Title
WO/2018/220531A1
The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a com...  
WO/2018/222795A1
Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are metho...  
WO/2018/219927A1
The present invention relates to (hetero)arylalkylamino-pyrazolopyridazine derivatives having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ 1 subunit, of the voltage-gated calcium channel and the N...  
WO/2018/220355A1
The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquiti...  
WO/2018/218696A1
Provided is a ligand compound ofα7 nicotinic acetylcholine receptor, which can be represented by any one of the following general formulas, wherein (1) represents a halogen. The ligand compound is an improved ligand compound of α7 nico...  
WO/2018/219921A1
The present invention relates to substituted pyrrolidinyl and piperidinyl pyrazolo[3,4-d]pyridazine derivatives having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated ...  
WO/2018/222598A1
The present disclosure provides, inter alia, Compounds of Formula (I) (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including th...  
WO/2018/222876A1
Described herein are fused bicyclic compounds, compositions, and methods for their preparation. Described herein are processes for the synthesis of FXR modulatators.  
WO/2018/221433A1
Provided is a novel compound, and a pharmaceutically acceptable salt thereof, that has an action of reducing blood sugar and the like, and that is useful as a therapeutic and/or preventive medicine for diseases such as diabetes. Provided...  
WO/2018/222601A1
The present disclosure provides, inter alia, Compounds of Formula (I) (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including th...  
WO/2018/214846A1
Provided is an imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine compound of general formula (I). The compound can be used in treating a cell proliferative disorder and is a cyclin-dependent kinase (CDK) inhibitor with broad-spectrum and strong ...  
WO/2018/215389A1
Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and...  
WO/2018/216800A1
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...  
WO/2018/215390A1
Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and...  
WO/2018/214796A1
The present invention provides a class of isoindolone-imide ring-1,3-dione-2-ene compounds, a preparation method, pharmaceutical composition and use thereof. Specifically, the present invention provides a class of compounds of the follow...  
WO/2018/218038A1
The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNKl, MNK2, or both are inhibited in the genet...  
WO/2018/216035A1
The present invention disclosed an assembly comprising the tetraphenylporphyrin and fullerene (C60) and a process for the preparation thereof. The present invention further disclosed an organic Field-Effect Transistor (OFET) comprising a...  
WO/2018/215800A1
The present invention relates to certain compounds that function as inhibitors of bacterial metallo-beta-lactamases. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions c...  
WO/2018/218133A1
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure...  
WO/2018/216679A1
The purpose of the present invention is to provide a ligand which can bond interfaces each formed between different types of nanoparticles to each other, or can bond interfaces each formed between different types of bulks to each other, ...  
WO/2018/215433A1
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-...  
WO/2018/218251A1
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-...  
WO/2018/218205A1
The present disclosure relates to various solid state forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol...  
WO/2018/218104A1
The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.  
WO/2018/217700A1
The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula (I), where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods ...  
WO/2018/210298A1
The present invention relates to a heteroaryl-pyrazole derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a new heteroaryl-pyrazole derivative as shown in formu...  
WO/2018/210659A1
Heteroaryl compounds as agrochemical fungicides Formula (I) The present invention relates to heteroaryl compounds of formula (I) or a compound in the form of a stereoisomer, an agriculturally acceptable salt, a tautomer, an isotopic form...  
WO/2018/210661A1
The present invention relates to heteroaryl compounds of formula (I) or a compound in the form of a stereoisomer, an agriculturally acceptable salt, a tautomer, an isotopic form, a N-oxide, a S- oxide, a prodrug or mixture thereof. The p...  
WO/2018/209927A1
The present invention provides a polyphthalocyanine compound, a compound of a double-layer sandwiched structure and a preparation method therefor, an organic field-effect transistor and a preparation method therefor, and s display device...  
WO/2018/209809A1
The present application relates to a polycrystalline mesylate of a phosphodiesterase type 5 inhibitor. The chemical name of the phosphodiesterase type 5 inhibitor is 5-[2-ethoxy-5-(4-methylpiperazin-1-yl-thiocarbonyl)phenyl]-1 -methyl-3-...  
WO/2018/211323A1
Described herein are heterocyclic compounds, compositions, and methods for their use for treatment of disease.  
WO/2018/210314A1
The present invention relates to the field of pharmaceutical chemistry, and provides a five- and six-membered aza-aromatic compound, a preparation method therefor, a pharmaceutical composition, and an application. Specifically, the prese...  
WO/2018/210660A1
The present invention relates to heteroaryl compounds of formula (I) or a compound in the form of a stereoisomer, an agriculturally acceptable salt, a tautomer, an isotopic form, a N-oxide, a S-oxide, a prodrug or mixture thereof. The pr...  
WO/2018/212333A1
Production and purification methods for efinaconazole are provided by which high-purity efinaconazole can be obtained in high yield through a simple procedure using a specific impurity as an index, the methods being suitable for industri...  
WO/2018/213712A1
Compounds of formula: (I) (II) are useful as antitumor agents. In these compounds, R10 is (a) (C1-C10) hydrocarbyl, (C1-C10)halohydrocarbyl, (C1-C6)hydroxyalkyl, or (III) or R10 is (b), (IV) in which Q and A are linkers and Ar is optiona...  
WO/2018/213634A1
The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.  
WO/2018/210658A1
The present invention relates to heteroaryl compounds of formula (I) or a compound in the form of a stereoisomer, an agriculturally acceptable salt, a tautomer, an isotopic form, a N-oxide, a S-oxide, a prodrug or mixture thereof. The pr...  
WO/2018/209961A1
Disclosed is a pyrazolo[3,4-d]pyrimidine derivative as represented by formula (I). The compound provided by the present invention has significant growth inhibiting, apoptosis promoting and cell proliferation slowing effects on tumor cell...  
WO/2018/208132A1
The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and...  
WO/2018/206820A1
The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (la), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (la) and the ph...  
WO/2018/206479A1
The present invention relates to compounds of formula (I), wherein the variables are defined as given in the description and claims. The invention further relates to uses, processes and composition for compounds (I).  
WO/2018/206348A1
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared...  
WO/2018/206739A1
A compound or its acid addition salt of the general formula (I), wherein R1 represents phenyl substituted with one or two substituents selected from the group consisting of halogen and C1-C3 alkoxyl, or 6-membered heteroaryl with 1 or 2 ...  
WO/2018/205938A1
Disclosed are a PARP inhibitor, and a pharmaceutical composition, a preparation method and the use thereof. Also disclosed are a compound as shown in formula I of the present invention, and a pharmaceutically acceptable salt, an N-oxide,...  
WO/2018/209239A1
The present disclosure relates to derivatized agelastatin compounds and methods for the treatment, prevention, or delay of cancer, comprising administering a therapeutically effect amount of the derivatized agelastatin compounds, a pharm...  
WO/2018/209119A1
Disclosed are methods of treating a disorder or disease associated with myotonic dystrophy. Methods of treating a CNS dysfunction and/or cognitive impairment associated with myotonic dystrophy in a subject comprising administering a ther...  
WO/2018/202540A1
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared...  
WO/2018/202039A1
Disclosed in the present invention is a compound as represented by formula (A), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof. The new compound as represented by formula (A) disclosed in t...  
WO/2018/202428A1
Fungicidal mixture comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles The present invention relates to fungicidal mixtures comprising at least one substituted 3- phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles (compounds ...  
WO/2018/202155A1
The present invention relates to a bicyclic nucleocapsid inhibitor and the use of the same as a drug in the treatment of hepatitis B. In particular, disclosed is a compound having the structure as shown in chemical formula A, or a stereo...  

Matches 1 - 50 out of 37,134